ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET FORECAST 2021-2028

The Asia Pacific non-alcoholic steatohepatitis (NASH) biomarker market is estimated to project a CAGR of 23.00% during the forecast period, 2021-2028. The enhanced healthcare infrastructure, improving economic conditions, surging diagnosis rates, and the surging prevalence of NASH are projected to drive the market growth.

To learn more about this report, request a free sample copy

China, Australia & New Zealand, Japan, Indonesia, Vietnam, South Korea, Thailand, India, and Rest of Asia Pacific, are assessed for the Asia Pacific non-alcoholic steatohepatitis (NASH) biomarker market growth analysis. In China, the growing prevalence and incidence of NASG and other types of nonalcoholic fatty liver diseases (NAFLD) influence market growth. As per a study by Jing Wu et al. in 2018, NAFLD reached 44.7% among the population from 20.7%. Further, in another study by the Journal of Gastroenterology and Hepatology in 2015, NAFLD was 2.1% among children. The prevalence was higher among obese children. With the rising obesity and metabolic issues, the number of fatty liver disease is set to increase. Such factors are expected to boost the market growth in China. In Indonesia, weight problems increased from 2007 to 2018, according to the Basic Health Survey (Riskesdas) 2018. Also, as per the same study, obesity recorded an increase from 14.8% in 2013 to 21.8% in 2018. Moreover, diabetes mellitus (DM) has increased in the last few years. In Vietnam, the market growth is attributed to the prevalence of diabetes and obesity. Diabetes was highly prevalent in 2015, resulting in almost 53, 458 deaths.

Cadila Healthcare (Cadila) offers a range of healthcare products. The operations of the company come under the pharmaceutical segment. It is also involved in manufacturing pharmaceutical products for pain management, gastrointestinal, cardiovascular, anti-infectives, etc. The company develops the formulation for abbreviated new drug applications (ANDA) candidates. It is headquartered in Ahmedabad, India.

 

TABLE OF CONTENTS
  1. RESEARCH SCOPE & METHODOLOGY
    1. STUDY OBJECTIVES
    2. SCOPE OF STUDY
    3. METHODOLOGY
    4. ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    1. MARKET SIZE & ESTIMATES
    2. MARKET OVERVIEW
  3. MARKET DYNAMICS
    1.    KEY DRIVERS
      1. GROWING NASH AFFECTED POPULATION
      2. SURGING PREVALENCE OF OBESITY AND DIABETES
      3. INCREASING OCCURRENCE OF CHRONIC DISEASES
      4. SURGING AWARENESS OF NON-ALCOHOLIC FATTY LIVER DISEASE
    2.    KEY RESTRAINTS
      1. SIDE-EFFECTS AND RISKS ASSOCIATED WITH NASH THERAPEUTICS
      2. LACK OF SPECIALIZED DIAGNOSTIC TEST FOR NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
  4. KEY ANALYTICS
    1.    PORTER’S FIVE FORCES ANALYSIS
      1. THREAT OF NEW ENTRY
      2. THREAT OF SUBSTITUTION
      3. BUYER’S POWER
      4. SUPPLIER’S POWER
      5. COMPETITIVE RIVALRY
    2. IMPACT OF COVID-19 ON NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET
    3. OPPORTUNITY MATRIX
    4. VENDOR LANDSCAPE
    5. KEY INVESTMENT INSIGHTS
  5. MARKET BY TYPE
    1. SERUM BIOMARKER
    2. HEPATIC FIBROSIS BIOMARKER
    3. APOPTOSIS BIOMARKER
    4. OXIDATIVE STRESS BIOMARKER
    5. OTHER TYPES
  6. MARKET BY END-USER
    1. PHARMA & CRO INDUSTRY
    2. DIAGNOSTIC LAB
    3. ACADEMIC RESEARCH KEY
    4. HOSPITAL
  7. GEOGRAPHICAL ANALYSIS
    1.    ASIA PACIFIC
      1. MARKET SIZE & ESTIMATES
      2. KEY GROWTH ENABLERS
      3. KEY CHALLENGES
      4. KEY PLAYERS
      5.    COUNTRY ANALYSIS
        1. CHINA
        2. JAPAN
        3. AUSTRALIA & NEW ZEALAND
        4. INDIA
        5. SOUTH KOREA
        6. THAILAND
        7. INDONESIA
        8. VIETNAM
        9. REST OF ASIA PACIFIC
  8. COMPETITIVE LANDSCAPE
    1.    KEY STRATEGIC DEVELOPMENTS
      1. MERGER & ACQUISITIONS
      2. PRODUCT LAUNCH & DEVELOPMENTS
      3. PARTNERSHIP, CONTRACT/AGREEMENT & COLLABORATION
      4. BUSINESS EXPANSION/ APPROVAL/ ANNOUNCEMENT
    2.    COMPANY PROFILE
      1. ALLERGAN PLC (ACQUIRED BY ABBVIE)
      2. ASTRAZENECA
      3. BRISTOL-MYERS SQUIBB COMPANY
      4. GENFIT SA
      5. GILEAD SCIENCES INC
      6. MADRIGAL PHARMACEUTICALS
      7. MERCK & CO
      8. NOVARTIS AG
      9. NOVO NORDISK
      10. PFIZER INC
      11. SIEMENS HEALTHINEERS
      12. VIKING THERAPEUTICS
      13. ZYDUS CADILA
LIST OF TABLES

TABLE 1: MARKET SNAPSHOT – NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER

TABLE 2: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 3: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 4: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY END-USER, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 5: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY END-USER, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 6: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 7: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 8: LEADING PLAYERS OPERATING IN ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET

LIST OF FIGURES

FIGURE 1: PORTER’S FIVE FORCE ANALYSIS

FIGURE 2: OPPORTUNITY MATRIX

FIGURE 3: VENDOR LANDSCAPE

FIGURE 4: KEY INVESTMENT INSIGHTS

FIGURE 5: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, IN 2020

FIGURE 6: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY SERUM BIOMARKER, 2021-2028 (IN $ MILLION)

FIGURE 7: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY HEPATIC FIBROSIS BIOMARKER, 2021-2028 (IN $ MILLION)

FIGURE 8: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY APOPTOSIS BIOMARKER, 2021-2028 (IN $ MILLION)

FIGURE 9: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY OXIDATIVE STRESS BIOMARKER, 2021-2028 (IN $ MILLION)

FIGURE 10: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY OTHER TYPES, 2021-2028 (IN $ MILLION)

FIGURE 11: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY END-USER, IN 2020

FIGURE 12: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY PHARMA & CRO INDUSTRY, 2021-2028 (IN $ MILLION)

FIGURE 13: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY DIAGNOSTIC LAB, 2021-2028 (IN $ MILLION)

FIGURE 14: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY ACADEMIC RESEARCH KEY, 2021-2028 (IN $ MILLION)

FIGURE 15: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY HOSPITAL, 2021-2028 (IN $ MILLION)

FIGURE 16: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)

FIGURE 17: CHINA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)

FIGURE 18: JAPAN NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)

FIGURE 19: AUSTRALIA & NEW ZEALAND NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)

FIGURE 20: INDIA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)

FIGURE 21: SOUTH KOREA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)

FIGURE 22: THAILAND NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)

FIGURE 23: INDONESIA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)

FIGURE 24: VIETNAM NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)

FIGURE 25: REST OF ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)

Request For A Free Sample